Two-months quality of life of COVID-19 invasively ventilated survivors; an Italian single-center study.
COVID-19
/ complications
Critical Care
/ methods
Female
Follow-Up Studies
Humans
Italy
Male
Malnutrition
/ complications
Middle Aged
Prospective Studies
Quality of Life
Recovery of Function
Respiration, Artificial
/ statistics & numerical data
Surveys and Questionnaires
Survivors
/ statistics & numerical data
Acute respiratory distress syndrome
COVID-19
critically ill patients
follow-up
intensive care
quality-of-life
Journal
Acta anaesthesiologica Scandinavica
ISSN: 1399-6576
Titre abrégé: Acta Anaesthesiol Scand
Pays: England
ID NLM: 0370270
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
revised:
16
02
2021
received:
11
09
2020
accepted:
17
02
2021
pubmed:
4
3
2021
medline:
14
8
2021
entrez:
3
3
2021
Statut:
ppublish
Résumé
COVID-19 disease can lead to severe functional impairments after discharge. We assessed the quality of life of invasively ventilated COVID-19 ARDS survivors. We carried out a prospective follow-up study of the patients admitted to the Intensive Care Units (ICUs) of a teaching hospital. Patients affected by COVID-19 ARDS who required invasive ventilation and were successfully discharged home were assessed through the telephone administration of validated tests. We explored survival, functional outcomes, return to work, quality of life, cognitive and psychological sequelae. The main variables of interest were the following: demographics, severity scores, laboratory values, comorbidities, schooling, working status, treatments received during ICU stay, complications, and psychological, cognitive, functional outcomes. Out of 116 consecutive invasively ventilated patients, overall survival was 65/116 (56%) with no death occurring after hospital discharge. Forty-two patients were already discharged home with a median follow-up time of 61 (51-71) days after ICU discharge and 39 of them accepted to be interviewed. Only one patient (1/39) experienced cognitive decline. The vast majority of patients reported no difficulty in walking (32/35:82%), self-care (33/39:85%), and usual activities (30/39:78%). All patients were either malnourished (15/39:38%) or at risk for malnutrition (24/39:62%). Exertional dyspnea was present in 20/39 (51%) patients. 19/39 (49%) reported alterations in senses of smell and/or taste either before or after hospitalization. Invasively ventilated COVID-19 ARDS survivors have an overall good recovery at a 2-months follow-up which is better than what was previously reported in non-COVID-19 ARDS patients.
Sections du résumé
BACKGROUND
COVID-19 disease can lead to severe functional impairments after discharge. We assessed the quality of life of invasively ventilated COVID-19 ARDS survivors.
METHODS
We carried out a prospective follow-up study of the patients admitted to the Intensive Care Units (ICUs) of a teaching hospital. Patients affected by COVID-19 ARDS who required invasive ventilation and were successfully discharged home were assessed through the telephone administration of validated tests. We explored survival, functional outcomes, return to work, quality of life, cognitive and psychological sequelae. The main variables of interest were the following: demographics, severity scores, laboratory values, comorbidities, schooling, working status, treatments received during ICU stay, complications, and psychological, cognitive, functional outcomes.
RESULTS
Out of 116 consecutive invasively ventilated patients, overall survival was 65/116 (56%) with no death occurring after hospital discharge. Forty-two patients were already discharged home with a median follow-up time of 61 (51-71) days after ICU discharge and 39 of them accepted to be interviewed. Only one patient (1/39) experienced cognitive decline. The vast majority of patients reported no difficulty in walking (32/35:82%), self-care (33/39:85%), and usual activities (30/39:78%). All patients were either malnourished (15/39:38%) or at risk for malnutrition (24/39:62%). Exertional dyspnea was present in 20/39 (51%) patients. 19/39 (49%) reported alterations in senses of smell and/or taste either before or after hospitalization.
CONCLUSIONS
Invasively ventilated COVID-19 ARDS survivors have an overall good recovery at a 2-months follow-up which is better than what was previously reported in non-COVID-19 ARDS patients.
Identifiants
pubmed: 33655487
doi: 10.1111/aas.13812
pmc: PMC8014684
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
912-920Informations de copyright
© 2021 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
Crit Care Med. 1998 Apr;26(4):651-9
pubmed: 9559601
JAMA. 2020 Jun 9;323(22):2338-2340
pubmed: 32412606
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
PLoS One. 2016 Oct 10;11(10):e0161645
pubmed: 27723815
Am J Respir Crit Care Med. 2016 Oct 1;194(7):831-844
pubmed: 26974173
Acta Anaesthesiol Scand. 2021 Aug;65(7):912-920
pubmed: 33655487
Lancet. 2020 Feb 29;395(10225):685
pubmed: 32059800
Nat Rev Dis Primers. 2020 Jul 15;6(1):60
pubmed: 32669623
J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):285-93
pubmed: 6453957
Crit Care Resusc. 2020 Sep;22(3):253-256
pubmed: 32900332
Cleve Clin J Med. 2020 Aug 5;:
pubmed: 32759175
Crit Care Resusc. 2020 Sep;22(3):200-211
pubmed: 32900326
Phys Ther. 1984 Jan;64(1):35-40
pubmed: 6691052
JAMA Intern Med. 2020 Oct 1;180(10):1345-1355
pubmed: 32667669
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Am J Respir Crit Care Med. 2021 Jan 1;203(1):54-66
pubmed: 33119402
Value Health. 2013 Jul-Aug;16(5):814-22
pubmed: 23947975
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
BMC Public Health. 2020 Jun 5;20(1):861
pubmed: 32503583
Respir Care. 2012 May;57(5):764-72
pubmed: 22152275
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
Med Sci Sports Exerc. 1982;14(5):377-81
pubmed: 7154893
Sleep. 2011 May 01;34(5):601-8
pubmed: 21532953
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
J Nerv Ment Dis. 2017 Oct;205(10):780-787
pubmed: 28682981
Scand J Work Environ Health. 2014 May 1;40(3):215-29
pubmed: 24599261
J Neurotrauma. 1998 Aug;15(8):573-85
pubmed: 9726257
J Crit Care. 2015 Aug;30(4):793-8
pubmed: 25981443
J Nutr Health Aging. 2009 Nov;13(9):782-8
pubmed: 19812868
Crit Care Med. 2020 Aug;48(8):1196-1202
pubmed: 32697491
N Engl J Med. 2011 Apr 7;364(14):1293-304
pubmed: 21470008
Crit Care Resusc. 2020 Apr 01;22(2):91-94
pubmed: 32227819
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
Crit Care Med. 2012 Feb;40(2):502-9
pubmed: 21946660
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Acta Biomed. 2020 Jul 20;91(9-S):22-28
pubmed: 32701913
Intensive Care Med. 2013 Nov;39(11):1916-24
pubmed: 23925544
Crit Care Resusc. 2020 Apr 15;22(2):95-97
pubmed: 32294809
Minerva Med. 2022 Apr;113(2):281-290
pubmed: 32996727
Int J Geriatr Psychiatry. 2001 Feb;16(2):166-7
pubmed: 11241721
J Crit Care. 2019 Oct;53:149-154
pubmed: 31247513
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Anaesth Crit Care Pain Med. 2020 Dec;39(6):740-741
pubmed: 33049394
JAMA. 1994 Apr 20;271(15):1200-3
pubmed: 7818629
JAMA. 1993 Dec 22-29;270(24):2957-63
pubmed: 8254858
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Clin Immunol. 2020 Aug;217:108509
pubmed: 32535188
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
J Rehabil Med. 2020 Apr 15;52(4):jrm00044
pubmed: 32286675
Heart Lung. 2020 Nov - Dec;49(6):883-884
pubmed: 32690219